JNJ-80038114

N/A

Report date: 2022/07/08 22:10:06

Base Information

Drug NameJNJ-80038114
Drug Alias NameJNJ-80038114
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionAnti-PSMAT lymphocyte replacements
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A